Photo from wikipedia
About 20%‐30% of diffuse large B‐cell lymphoma (DLBCL) patients experience early disease progression despite R‐CHOP chemotherapy treatment. Revised international prognostic index (R‐IPI) score could risk stratify DLBCL patients but does… Click to show full abstract
About 20%‐30% of diffuse large B‐cell lymphoma (DLBCL) patients experience early disease progression despite R‐CHOP chemotherapy treatment. Revised international prognostic index (R‐IPI) score could risk stratify DLBCL patients but does not identify exactly which patient will be resistant to R‐CHOP therapy or experience early relapse.
Keywords:
chop chemotherapy;
early relapse;
large cell;
diffuse large;
cell lymphoma
Journal Title: International Journal of Clinical Practice
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Clinical Practice
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!